Targeting secondary immune responses to cetuximab: CD137 and the outside story.
Level V
Where this comes from
- Record sourced from PubMed, PMID 24837438.
- Also identified by DOI 10.1172/JCI76264 and PMC identifier 4089450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cetuximab is a murine-human chimeric IgG1 mAb directed against the EGFR that is approved for use in patients with colorectal and head and neck carcinomas. While some patients benefit greatly from cetuximab, many do not; therefore, strategies to increase the efficacy of this drug are of great clinical interest. In this issue of the JCI, Kohrt and colleagues report a strategy for enhancing the secondary immune response to cetuximab that involves sequential targeting with an agonist mAb against CD137 expressed on NK and T cells.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Tumor Necrosis Factor Receptor Superfamily, Member 9